Grifols SA is undergoing a critical operational and financial reset following the severe market disruption triggered by Gotham City Research's short-seller report in early 2024. While the company has demonstrated solid underlying demand in its core Biopharma business—driven by double-digit growth in its immunoglobulin franchise and the successful US launch of Biotest's Yimmugo—it remains highly leveraged with a net debt of approximately EUR 7.7 billion. Management's strategic focus is heavily tilted toward deleveraging, targeting a leverage ratio of 3.5x or lower by 2027, and exploring a potential US IPO of a minority stake in its North American Biopharma business to unlock unrecognized value. Although operational execution is stable and refinancing of 2027 maturities has been successfully completed, the high debt burden, ongoing litigation, and regional pricing pressures (such as albumin in China) warrant a cautious Hold stance until deleveraging milestones are more firmly established.